 NEW YORK, Dec. 07, 2020 GLOBE NEWSWIRE -- Delcath Systems, Inc. NASDAQ: DCTH, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations. In his most recent role, Mr. Muir was Director of Sales for the Embolics Interventional Oncology business unit of BTG plc where he played a key role in growing that business from 40 million to 180 million at which time BTG was acquired by Boston Scientific. 